Pédiatrie Neuroblastomes J1O-MC-JZHD A Phase 1 Study of;Aurora Kinase A Inhibitor LY3295668 erbumine as a Single;Agent and in Combination in Patients with;Relapsed/Refractory Neuroblastoma Paris ISABELLE AERTS
Hématologie Leucémie AML LI-1 A PROGRAMME OF DEVELOPMENT FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME Saint-Cloud JACQUES VARGAFTIG
Hématologie Leucémie Backbone Inter-Group-1 (BIG-1) Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial Saint-Cloud JACQUES VARGAFTIG
Hématologie Leucémie FAST French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study Saint-Cloud SANDRA MALAK
Pédiatrie Neuroblastomes HR-NBL2 High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Paris GUDRUN SCHLEIERMACHER
Pédiatrie Neuroblastomes EUSA-PASS (EUSA-DB-0001) A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta Paris GUDRUN SCHLEIERMACHER
Pédiatrie Neuroblastomes NANT 2015-02 (IC 2018-05) Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma Paris GUDRUN SCHLEIERMACHER